Waldron Private Wealth LLC Sells 760 Shares of Johnson & Johnson (NYSE:JNJ)

Waldron Private Wealth LLC cut its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 1.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,800 shares of the company’s stock after selling 760 shares during the period. Waldron Private Wealth LLC’s holdings in Johnson & Johnson were worth $5,756,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AMF Tjanstepension AB lifted its stake in Johnson & Johnson by 14.2% in the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after acquiring an additional 52,997 shares during the period. Czech National Bank lifted its position in shares of Johnson & Johnson by 6.9% in the 3rd quarter. Czech National Bank now owns 490,381 shares of the company’s stock worth $79,471,000 after purchasing an additional 31,766 shares during the period. GAMMA Investing LLC increased its holdings in Johnson & Johnson by 40.4% during the third quarter. GAMMA Investing LLC now owns 35,924 shares of the company’s stock valued at $5,822,000 after buying an additional 10,332 shares during the period. Davis Investment Partners LLC raised its stake in Johnson & Johnson by 2.4% in the third quarter. Davis Investment Partners LLC now owns 3,118 shares of the company’s stock worth $503,000 after buying an additional 72 shares in the last quarter. Finally, Alpha Financial Partners LLC purchased a new stake in Johnson & Johnson during the third quarter worth $209,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

JNJ has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Bank of America cut their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, January 23rd. Raymond James lowered their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Read Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Stock Down 0.2 %

Shares of NYSE:JNJ opened at $151.82 on Tuesday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The stock has a market cap of $365.53 billion, a P/E ratio of 22.83, a PEG ratio of 2.44 and a beta of 0.52. The business has a fifty day moving average of $147.61 and a two-hundred day moving average of $156.12. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.29 earnings per share. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.27%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.